Birth Outcomes for Pregnant Women Using Tenofovir-Emtricitabine
In a previous trial of antiretroviral therapy involving pregnant women with HIV infection, those randomly assigned to receive tenofovir, emtricitabine, and ritonavir-boosted lopinavir (TDF-FTC-LPV/r) had infants at greater risk for very premature birth and death within 14 days after delivery than those assigned to receive zidovudine, lamivudine, and ritonavir-boosted lopinavir (ZDV-3TC-LPV/r). A new study from two U.S.-based cohort studies compared the risk of adverse birth outcomes among infants with in utero exposure to ZDV-3TC-LPV/r, TDF-FTC-LPV/r, or TDF-FTC with ritonavir-boosted atazanavir (ATV/r). They found no significant differences between regimens in the risk of very preterm birth or very low birth weight.
Citation:
Rough K, Seage GR 3rd, Williams PL, Hernandez-Diaz S, Huo Y, Chadwick EG, Currier JS, Hoffman RM, Barr E, Shapiro DE, Patel K; PHACS and the IMPAACT P1025 Study Teams. Birth outcomes for pregnant women with HIV using tenofovir-emtricitabine. N Engl J Med. 2018 Apr 26;378(17):1593-1603.
Original Article (Subscription may be required)
